UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Legal Issues concerning DROMLAN under the Antarctic Treaty System

The yearbook of polar law, 2020-12, Vol.12 (1), p.61-74

Inagaki, Osamu

2020

Volltextzugriff (PDF)

Assessing Japan’s Arctic Engagement during the ArCS Project (2015–2020)

The yearbook of polar law, 2020-12, Vol.12 (1), p.328-348

2020

Volltextzugriff (PDF)

Meetin4gs of the SCAR standing committee on the humanities and social sciences (SC-HASS) PoLSciNex action group in 2019

Polar journal, 2020-01, Vol.10 (1), p.191-195

2020

Volltextzugriff (PDF)

Importance of Post-Marketing Studies in Gathering of Clinical Evidences for Proper Usage of Anti-Cancer Drugs, and the StudyRequirements for Their Credibility

Gan to kagaku ryoho, 2016-04, Vol.43 (4), p.480

Inagaki, Osamu

2016

Volltextzugriff (PDF)

S22-2 Measures for Promoting Early-Stage Exploratory Clinical Studies and Preventing Japanese Clinical Trials' Hollowing Out --From the View Point of Pharma Industries

Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, Vol.42(2), pp.85-86

INAGAKI, Osamu

2011

Volltextzugriff (PDF)

Expectation for the Drug Development Activity in Academia

YAKUGAKU ZASSHI, 2013/02/01, Vol.133(2), pp.213-219

Inagaki, Osamu

2013

Volltextzugriff (PDF)

Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease

Biological and Pharmaceutical Bulletin, 2005, Vol.28(2), pp.367-369

2005

Volltextzugriff (PDF)

Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease

Biological & Pharmaceutical Bulletin, 2005, Vol.28 (2), p.367-369

2005

Volltextzugriff (PDF)

Effects of Angiotensin II Type 1 Receptor Antagonist, YM358, on Cardiac Hypertrophy and Dysfunction after Myocardial Infarction in Rats

Biological and Pharmaceutical Bulletin, 2002, Vol.25(7), pp.857-860

2002

Volltextzugriff (PDF)

In Vitro and in Vivo Vasodilatory Activity of barnidipine and Its Enantiomers

Biological and Pharmaceutical Bulletin, 1999/02/15, Vol.22(2), pp.151-156

1999

Volltextzugriff (PDF)

Ex vivo occupancy by tamsulosin of α1-adrenoceptors in rat tissues in relation to the plasma concentration

Life sciences (1973), 1998-11, Vol.63 (24), p.2147-2155

1998

Volltextzugriff (PDF)

Antithrombotic and thrombolytic efficacy of YM-254890, a Gq/11 inhibitor, in a rat model of arterial thrombosis

Thrombosis and haemostasis, 2003, Vol.90 (9), p.406-413

2003

Volltextzugriff (PDF)

COMPARATIVE STUDY ON α1-ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA

Clinical and experimental pharmacology & physiology, 1994-05, Vol.21 (5), p.405-411

1994

Volltextzugriff (PDF)

アカデミア発の創薬への期待

YAKUGAKU ZASSHI, 2013/02/01, Vol.133(2), pp.213-219

稲垣, 治

2013

Volltextzugriff (PDF)

Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys

European journal of pharmacology, 1997-10, Vol.336 (2-3), p.169-176

1997

Volltextzugriff (PDF)

Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs

European journal of pharmacology, 1997-09, Vol.335 (2), p.175-184

1997

Volltextzugriff (PDF)

製薬企業としてのレギュラトリーサイエンス教育への要望と，レギュラトリーサイエンス教育を受けた人材のニーズ

ファルマシア, 2015, Vol.51(7), pp.675-678

稲垣, 治

2015

Volltextzugriff (PDF)

Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats

European journal of pharmacology, 2003-02, Vol.461 (2), p.191-195

2003

Volltextzugriff (PDF)

Effects of YM358, an Angiotensin II Type 1 (AT1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models

Biological and Pharmaceutical Bulletin, 2000/02/01, Vol.23(2), pp.174-181

2000

Volltextzugriff (PDF)

Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist

European journal of pharmacology, 1997-09, Vol.335 (2), p.167-173

1997

Volltextzugriff (PDF)

Studies on Nonpeptide Angiotensin II Receptor Antagonists. III. Synthesis and Biological Evaluation of 5-Alkylidene-3, 5-dihydro-4H-imidazol-4-one-Derivatives

Chemical and Pharmaceutical Bulletin, 1998/05/15, Vol.46(5), pp.777-781

1998

Volltextzugriff (PDF)

Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis

Thrombosis and haemostasis, 1998-03, Vol.79 (3), p.663-667

1998

Volltextzugriff (PDF)

Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys

Thrombosis and haemostasis, 1996, Vol.75 (4), p.679-684

1996

Volltextzugriff (PDF)

Studies on nonpeptide angiotensin II receptor antagonists. I. Synthesis and biological evaluation of pyrazolo[1,5-b][1,2,4]triazole derivatives with alkyl substituents

Chemical & pharmaceutical bulletin, 1998, Vol.46 (1), p.69-78

1998

Volltextzugriff (PDF)

Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Journal of medicinal chemistry, 1986-12, Vol.29 (12), p.2504-2511

1986

Volltextzugriff (PDF)

1 – 25 von 521

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(325)
Mit Volltextzugriff
(462)

Publikationsform

Sprache

Englisch
(435)
Japanisch
(106)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Legal Issues concerning DROMLAN under the Antarctic Treaty System

Assessing Japan’s Arctic Engagement during the ArCS Project (2015–2020)

Meetin4gs of the SCAR standing committee on the humanities and social sciences (SC-HASS) PoLSciNex action group in 2019

Importance of Post-Marketing Studies in Gathering of Clinical Evidences for Proper Usage of Anti-Cancer Drugs, and the StudyRequirements for Their Credibility

S22-2 Measures for Promoting Early-Stage Exploratory Clinical Studies and Preventing Japanese Clinical Trials' Hollowing Out --From the View Point of Pharma Industries

Expectation for the Drug Development Activity in Academia

Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease

Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease

Effects of Angiotensin II Type 1 Receptor Antagonist, YM358, on Cardiac Hypertrophy and Dysfunction after Myocardial Infarction in Rats

In Vitro and in Vivo Vasodilatory Activity of barnidipine and Its Enantiomers

Ex vivo occupancy by tamsulosin of α1-adrenoceptors in rat tissues in relation to the plasma concentration

Antithrombotic and thrombolytic efficacy of YM-254890, a Gq/11 inhibitor, in a rat model of arterial thrombosis

COMPARATIVE STUDY ON α1-ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA

アカデミア発の創薬への期待

Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys

Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs

製薬企業としてのレギュラトリーサイエンス教育への要望と，レギュラトリーサイエンス教育を受けた人材のニーズ

Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats

Effects of YM358, an Angiotensin II Type 1 (AT1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models

Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist

Studies on Nonpeptide Angiotensin II Receptor Antagonists. III. Synthesis and Biological Evaluation of 5-Alkylidene-3, 5-dihydro-4H-imidazol-4-one-Derivatives

Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis

Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys

Studies on nonpeptide angiotensin II receptor antagonists. I. Synthesis and biological evaluation of pyrazolo[1,5-b][1,2,4]triazole derivatives with alkyl substituents

Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Suchergebnisse filtern